Get a head start on next year with the just published 2014 Oncology Nursing Drug Handbook by Gail M. Wilkes and Margaret Barton-Burke. Written especially for nurses caring for patients with cancer, it uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation.
Updated annually, 2014 Oncology Nursing Drug Handbook provides valuable information on effective symptom management, patient education, and chemotherapy administration.
- New chapter on Chemobiotherapy for Noncancer Diseases: Rheumatoid Arthritis
- Specific drugs described in terms of their mechanism of action, metabolism, drug interactions, laboratory effects/interference, and special considerations
- Includes the most important and common drug side effects
- Greater discussion of fundamentals of malignant transformation, new molecular targets, and drugs in the pipeline
New drug entries include: enzalutamide, omacetaxine (Synribo), tbo-filgrastim (Netroval), ado-trastuzumab emtansine, aflibercept, bosutinib, cabozantinib, carfilzomib, dabrafenib, pomalidomide, ponatinib, regorafenib, trametinib, abatacept (Orencia), adalimumab (Humira), certolizumab pegol (CIMZA), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade), tocilizumab (Actemra), and tofacitinib (Xeljanz).
Want to learn more? Visit our website.